News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AB Science (AB.PA) Announces Recruitment of First Patient in Phase 3 Study of Masitinib in Multiple Myeloma



10/17/2011 10:40:36 AM

PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB)(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today recruitment of the first patient in the phase 3 study of masitinib in the treatment of patients with relapsing multiple myeloma who received one previous therapy. Thanks to the recruitment of the 1st patient in this study, AB Science is now conducting 8 phase 3 studies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES